Fahad J. Alharbi

Dr. Fahad J. Alharbi

Pathology, Prince Sultan Military Medical City Riyadh, Riyadh, Ar Riyāḑ, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2018 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
FAFahad J. Alharbi
Fahad J. Alharbi
SBShanat Baig
Shanat Baig
CAChristiane Auray‐Blais
Christiane Auray‐Blais
MBMichel Boutin
Michel Boutin
DWDouglas G. Ward
Douglas G. Ward
TGTarekegn Geberhiwot
Tarekegn Geberhiwot

1 July 2020 in Saudi Medical Journal
Verified
Journal Article
Open access
SMSarar Mohamed
Sarar Mohamed
WEWafa Elsheikh
Wafa Elsheikh
AAAida I. Al-Aqeel
Aida I. Al-Aqeel
AAAmal M. Alhashem
Amal M. Alhashem
AAAli Alodaib
Ali Alodaib
SASulaiman Almohaimeed
Sulaiman Almohaimeed
To determine the incidence of newborn screening (NBS) disorders and to study the key performance indicators of the program. This retrospective single-center study enrolled all infants who underwent NBS from January 2012 to December 2017 at Prince Sultan Military Medical City, Riyadh, Saudi Arabia. We screened 17 NBS disorders. Blood samples were collected 24 hours after birth. If the initial result was positive, a second sample was collected. True positive cases were immediately referred for medical management. Data were extracted from laboratory computerized and non-computerized records using case report forms. During the study period, 56632 infants underwent NBS with a coverage rate of 100%. Thirty-eight cases were confirmed. The incidence of congenital hypothyroidism was 1:3775. The positive predictive value for the detection of congenital hypothyroidism was 11.8%. Propionic aciduria was the most common metabolic disorder, with an incidence of 1:14158. Very long-chain acyl CoA dehydrogenase deficiency and glutaric aciduria type 1 had an incidence of 1:18877 each. Phenylketonuria, biotinidase deficiency, maple syrup urine disease, and citrullinemia had an incidence of 1:28316 each. However, galactosemia and 3-methyl crotonyl carboxylase deficiency had the lowest incidence of 1:56632. The NBS coverage rate at our facility was 100%. Congenital hypothyroidism was the most frequently detected disorder with an incidence that matches worldwide figures. The incidence of other inherited disorders was consistent with regional figures.

7 March 2024 in Medicina
Verified
Journal Article
Open access
PDF file
GAGhadeer Aljuraiban
Ghadeer Aljuraiban
FAFahad J. Alharbi
Fahad J. Alharbi
AAAli O. Aljohi
Ali O. Aljohi
AAAbdullah Z. Almeshari
Abdullah Z. Almeshari
MAMasoud N. Alotaibi
Masoud N. Alotaibi
MAMANAL ABUDAWOOD
MANAL ABUDAWOOD
Background and objectives: Low-grade inflammation is associated with metabolic disturbances like diabetes. The systemic immune-inflammation index (SII) has been proposed as a predictive tool to identify individuals at a greater risk of diabetes. This study aims to examine the association between SII and diabetes markers. Method and materials: We used retrospective data from a large cohort of adults (n = 3895) aged ≥18 in Saudi Arabia. The SII was calculated, and the markers of diabetes such as fasting blood glucose (FBG), insulin, and hemoglobin A1c (HbA1c) were included. Results: Across the quartiles of SII, FBG, insulin, and HbA1c were significantly higher in adults with higher compared to lower SII (p < 0.0001, p = 0.04, p < 0.0001, respectively). A two SD higher FBG was significantly associated with an SII difference of 47.7 (95% CI: (15.5, 91.9)). In subgroup analysis, this relationship prevailed in normal-weight participants and among those with normoglycemia and prediabetes but was attenuated in participants with diabetes. The association also prevailed in separate analyses for males and females but was stronger among females. Linear regression models showed no significant association between insulin, HbA1c, and SII. Conclusions: SII was associated with the markers of diabetes. The utility of SII for predicting diabetes can be confirmed with prospective cohort studies.

1 January 2020 in Clinica Chimica Acta
Verified
Journal Article
Closed access
FAFahad J. Alharbi
Fahad J. Alharbi
SBShanat Baig
Shanat Baig
SRSrinivasa B. Rambhatla
Srinivasa B. Rambhatla
RVRavi Vijapurapu
Ravi Vijapurapu
CAChristiane Auray-Blais
Christiane Auray-Blais
TGTarekegn Geberhiwot
Tarekegn Geberhiwot

6 June 2018 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
SBS Baig
S Baig
RVR Vijapurapu
R Vijapurapu
FAFahad J. Alharbi
Fahad J. Alharbi
SNSabrina Nordin
Sabrina Nordin
RKR Kozor
R Kozor
Richard SteedsRichard Steeds
Richard Steeds
Fabry disease (FD) has been a diagnostic challenge since it was first recognized in 1898, with patients traditionally suffering from considerable delay before a diagnosis is made. Cardiac involvement is the current leading cause of death in FD. A combination of improved enzyme assays, availability of genetic profiling, together with more organized clinical services for rare diseases, has led to a rapid growth in the prevalence of FD. The earlier and more frequent diagnosis of asymptomatic individuals before development of the phenotype has focussed attention on early detection of organ involvement and closer monitoring of disease progression. The high cost of enzyme replacement therapy at a time of constraint within many health economies, moreover, has challenged clinicians to target treatment effectively. This article provides an outline of FD for the general physician and summarizes the aetiology and pathology of FD, the cardiovascular consequences thereof, modalities used in diagnosis and then discusses current indications for treatment, including pharmacotherapy and device implantation.

12 July 2024 in Medicine
Verified
Journal Article
Open access
GAGhadeer Aljuraiban
Ghadeer Aljuraiban
FAFahad J. Alharbi
Fahad J. Alharbi
AAAli O. Aljohi
Ali O. Aljohi
AAAbdullah Z. Almeshari
Abdullah Z. Almeshari
AAAlsahli Alsahli
Alsahli Alsahli
Mahmoud AbulmeatyMahmoud Abulmeaty
Mahmoud Abulmeaty
High blood pressure (BP) and dyslipidemia are major risk factors for cardiovascular disease mortality. The systemic immune-inflammation index (SII) has been suggested as a predictive tool to identify those at risk for chronic diseases, however, its use for predicting high BP and dyslipidemia has not been thoroughly investigated. This study aimed to examine the association between SII and high BP as well as lipid markers. Retrospective hospital data from a large cohort (n = 3895) of Saudi adults aged ≥18 years were analyzed. Lipid markers (cholesterol, high-density lipoprotein, low-density lipoprotein [LDL]), systolic BP, and diastolic BP measures were extracted. When the sample was divided into quartiles of SII, cholesterol, triglycerides, and LDL were higher in those with a higher SII than in those with a lower SII ( P < .01). After adjusting for potential confounders, higher SII was significantly associated with higher odds of hypertension (odds ratio: 1.12, 95% confidence interval: 1.04–1.21) and elevated LDL (odds ratio: 1.07, 95% CI: 1.02–1.14), but not with elevated cholesterol. Across quartiles of SII, there was a significant trend between higher SII and the odds of hypertension in people with diabetes and those aged ≥65 years. The SII could be an economical predictive measure for identifying individuals at risk of hypertension and some aspects of dyslipidemia. Longitudinal studies are needed to confirm this relationship.